Iclaprim is a novel diaminopyrimidine, which inhibits bacterial dihydrofolate reductase, and it is active against Gram-positive pathogens including emerging drug-resistant pathogens. In vitro activity of iclaprim and comparators against 1365 Gram-positive clinical isolates from patients with skin and skin structure infections (SSSI) from the United States, Asia Pacific, Latin America, Europe, Africa or Middle East collected between 2013 and 2017 were tested. Susceptibility testing was performed according to the Clinical and Laboratory Standards Institute (CLSI) guidelines. Minimum inhibitory concentration (MIC) interpretations were based on CLSI criteria. MIC90 for all S.aureus, methicillin-susceptible S. aureus, methicillin-resistant S. aureus, Streptococcus pyogenes, S. agalactiae, S. anginosus, S. constellatus, S. dysgalactiae and S. intermedius were 0.12, 0.12, 0.5, 0.03, 0.5, ≤0.004, ≤0.004, 0.12, and 0.008 μg/ml, respectively. The MIC for iclaprim was 8 to 32-fold lower than trimethoprim, the only FDA approved dihydrofolate reductase inhibitor, against all Gram-positive isolates including resistant phenotypes. Iclaprim demonstrated lower MICs than trimethoprim against a collection (2013-2017) of Gram-positive clinical isolates from patients with SSSI from the United States, Asia Pacific, Latin America, and Europe.

中文翻译：

---

Iclaprim活性的全球监测：2013年至2017年从皮肤和皮肤结构感染患者中收集的革兰氏阳性病原体的体外敏感性。

Iclaprim是一种新型的二氨基嘧啶，可抑制细菌的二氢叶酸还原酶，并且对革兰氏阳性病原体（包括新兴的耐药菌）具有活性。测试了2013年至2017年间从美国，亚太地区，拉丁美洲，欧洲，非洲或中东有皮肤和皮肤结构感染（SSSI）患者的iclaprim和比较剂对1365革兰氏阳性临床分离株的体外活性。药敏试验是根据临床和实验室标准协会（CLSI）指南进行的。最小抑菌浓度（MIC）解释基于CLSI标准。所有金黄色葡萄球菌，耐甲氧西林金黄色葡萄球菌，耐甲氧西林金黄色葡萄球菌，化脓性链球菌，无乳链球菌，链球菌，链球菌，痢疾链球菌和S. MIC90。间质分别为0.12、0.12、0.5、0.03、0.5，≤0.004，≤0.004、0.12和0.008μg/ ml。对于所有包括耐药表型在内的革兰氏阳性菌，iclaprim的MIC比methmethprim低8％至32倍，后者是FDA唯一批准的二氢叶酸还原酶抑制剂。对于来自美国，亚太地区，拉丁美洲和欧洲的SSSI患者的革兰氏阳性临床分离株（2013-2017年），Iclaprim的MIC低于甲氧苄氨嘧啶。